Overview

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients

Status:
Recruiting

Trial end date:
2031-03-05

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Carboplatin
Durvalumab
Pembrolizumab
Pemetrexed
Tremelimumab